Clinical Trial Update: Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating pemigatinib with durvalumab for previously treated biliary tract carcinoma is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Pemazyre (pemigatinib)

Snippet

Sponsor: Eastern Hepatobiliary Surgery Hospital | Conditions: Biliary Tract Carcinoma, Cholangiocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING